#drug trial
Related Stories (12)
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com
September 30, 2026Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial - Reuters
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial Reuters
September 22, 2026EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks - Reuters
EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks Reuters
September 10, 2026Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - Reuters
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Reuters
September 3, 2026AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
August 27, 2026EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026Humana agrees not to reference Teva's Israel ties at US drug trial - Reuters
Humana agrees not to reference Teva's Israel ties at US drug trial Reuters
August 13, 2026Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial - Reuters
Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial Reuters
July 31, 2026US FDA advisers back Replimune skin cancer drug trial data - Reuters
US FDA advisers back Replimune skin cancer drug trial data Reuters
July 30, 2026Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings - Reuters
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings Reuters
June 29, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (9)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing